x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Psychopharmacology and Psychiatry Updates

Psychopharmacology Institute

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

health & fitness medicine

All Episodes

12:09

Rethinking Falls: Are Sleep Medications Really to Blame?

Psychopharmacology and Psychiatry Updates ·

2025/02/20

In this episode, we examine a groundbreaking Danish study that challenges the conventional belief that sedative medications increase fall risk in older adults. Could untreated insomnia, rather than the medications used to treat it, be the real culprit behind falls in elderly patients? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Insomnia in the Elderly: Do Sedatives Increase or Decrease Fall Risk?

en

10:42

Navigating Lamotrigine's Side Effects

Psychopharmacology and Psychiatry Updates ·

2025/02/15

In this episode, we explore lamotrigine's side effects and special considerations, particularly focusing on identifying dangerous skin reactions, pregnancy considerations, and overdose risks. Did you know that Asian populations may require special genetic screening before starting lamotrigine due to increased skin reaction risks? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects

en

09:23

Iloperidone in Bipolar Disorder: A New Treatment Option?

Psychopharmacology and Psychiatry Updates ·

2025/02/10

In this episode, we explore the efficacy and safety of iloperidone in treating bipolar disorder, examining new phase 3 trial data that reveals both promising results for mania symptoms and important considerations about side effects. Can this antipsychotic's favorable EPS profile outweigh its metabolic risks? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Iloperidone: A Potential Treatment Option for Bipolar

en

08:44

Lamotrigine: Pearls for Prescribing

Psychopharmacology and Psychiatry Updates ·

2025/02/05

In this episode, we explore the vital aspects of prescribing lamotrigine, from its mechanisms to titration schedules. Did you know that birth control pills can cut lamotrigine levels in half within just one week? Understanding these interactions is crucial for safe and effective treatment. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Understanding Lamotrigine Mechanisms and

en

10:19

Beyond Benzos: New Frontiers in Agitation Management

Psychopharmacology and Psychiatry Updates ·

2025/01/31

In this episode, we explore the pharmacological management of agitation in emergency settings, focusing on benzodiazepines and the novel medication dexmedetomidine. Did you know there's now a sublingual option that works through an entirely different mechanism than traditional anti-agitation medications? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies The Role of

en

11:40

KarXT: A New Dawn in Antipsychotic Treatment

Psychopharmacology and Psychiatry Updates ·

2025/01/26

In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial

en

10:50

Rethinking Agitation Management: From Force to...

Psychopharmacology and Psychiatry Updates ·

2025/01/21

In this episode, we explore evidence-based pharmacologic strategies for managing acute agitation in emergency settings, challenging the stigmatizing concept of “chemical restraints” and providing practical approaches to achieve optimal patient outcomes. Did you know that many agitated patients can actively participate in medication decisions, even during a crisis? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of

en

10:56

COVID Brain Fog: Repurposing Famotidine

Psychopharmacology and Psychiatry Updates ·

2025/01/16

In this episode, we explore how famotidine, a common heartburn medication, might help treat post-COVID brain fog. New research suggests this H2 blocker could improve cognitive function in recovering patients. But how does a stomach acid reducer potentially clear mental haziness? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 62 Famotidine for COVID-19 Brain Fog: A Promising Treatment Option

en

11:45

Beyond Restraints: De-Escalation in Behavioral...

Psychopharmacology and Psychiatry Updates ·

2025/01/11

In this episode, we explore nonpharmacologic strategies for managing agitated patients, focusing on verbal de-escalation techniques. Did you know that using physical restraints adds an average of four hours to an emergency department stay? Dr. Scott Zeller shares evidence-based approaches to transform crisis intervention in emergency settings. Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing

en

13:34

Rethinking Antipsychotic Dosing: Lessons from the...

Psychopharmacology and Psychiatry Updates ·

2025/01/06

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 62

en

11:06

Unraveling Agitation: Mania vs. Substance Use

Psychopharmacology and Psychiatry Updates ·

2025/01/01

In this episode, we explore the challenges of diagnosing and managing agitation in emergency settings, focusing on mood disorders and substance use. Dr. Scott Zeller shares insights on differentiating acute mania from substance-induced psychosis. How can clinicians navigate the complex interplay between psychiatric symptoms and substance effects in emergencies? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of

en

11:00

Pushing the Boundaries: Exploring High-Dose...

Psychopharmacology and Psychiatry Updates ·

2024/12/27

In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Is High-Dose Olanzapine an

en

15:19

The Psychodynamic Prescriber

Psychopharmacology and Psychiatry Updates ·

2024/12/22

In this episode, we explore how integrating psychodynamic principles into pharmacotherapy can enhance treatment outcomes. We discuss seven key features of psychodynamic psychotherapy and their application in routine psychiatric practice. How might understanding a patient's fantasies about their illness impact their response to medication? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication,

en

09:43

From Inpatient to Outpatient: Initiating...

Psychopharmacology and Psychiatry Updates ·

2024/12/17

In this episode, we explore strategies for discontinuing benzodiazepines in hospitalized elderly patients. We discuss a recent Israeli study that tested two interventions during inpatient stays. Can a simple hospital-based intervention lead to successful long-term medication changes? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Stopping Benzodiazepines and Z-Drugs in Hospitalized Elderly Patients

en

14:14

The Power of Alliance in Psychopharmacology

Psychopharmacology and Psychiatry Updates ·

2024/12/12

In this episode, we explore the critical role of therapeutic alliance in psychopharmacology. We discuss how factors like empathy, communication, and shared decision-making can significantly impact treatment outcomes. Did you know that a doctor's warm voice can increase appointment adherence by 162%? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills

en

08:27

Antipsychotics in Youth: Balancing Metabolic Risk

Psychopharmacology and Psychiatry Updates ·

2024/12/07

In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20

en

12:29

The Double-Edged Sword of Biological Explanations in...

Psychopharmacology and Psychiatry Updates ·

2024/12/02

In this episode, we explore the unexpected consequences of promoting a purely biological view of mental illness. How does framing mental health conditions as solely biological affect stigma, patient outcomes, and physician empathy? We delve into the complex interplay between biological and psychosocial factors in mental health treatment. Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication,

en

11:15

New Insights into Psychiatric and Cardiovascular...

Psychopharmacology and Psychiatry Updates ·

2024/11/27

In this episode, we explore the bidirectional relationship between psychiatric disorders and cardiovascular disease, discussing a groundbreaking study involving over 900,000 subjects. We ask: Can a mental health diagnosis increase your risk of heart disease? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership her Earn 0.5 CMEs: Quick Take Vol. 60 Psychiatric Disorders and Subsequent Risk of Cardiovascular Disease

en

16:55

Beyond the Pill: The Psychology of Psychopharmacology

Psychopharmacology and Psychiatry Updates ·

2024/11/22

In this episode, we explore the science behind the art of psychopharmacotherapy with Dr. David Mintz. We delve into how psychosocial factors, including the prescriber's approach, can significantly impact medication outcomes. Did you know that some psychiatrists achieve better results with placebos than others do with active medications? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication,

en

09:20

On Methylphenidate and Sleep: A Two-Year Study

Psychopharmacology and Psychiatry Updates ·

2024/11/17

In this episode, we explore the long-term effects of methylphenidate on sleep in children and adolescents with ADHD. Can stimulant medication actually improve sleep in ADHD patients? We dive into surprising research findings that challenge common assumptions about ADHD treatment and sleep disturbances. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Long-Term Effects of Methylphenidate on Sleep in Children and

en

420 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown